Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium

PharmacoEconomics

Volumn 29, Issue 10, 2011, Pages 895-911

  Hiligsmann, Mickaël ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Alendronic acid; Bisphosphonates; Cost utility; Denosumab; Osteoporosis; Postmenopausal osteoporosis; Risedronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BELGIUM; BONE DENSITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; FEMALE; GROUPS BY AGE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; WRIST FRACTURE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BELGIUM; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS;

EID: 80052785237     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11539980-000000000-00000     Document Type: Article

References (81)

1. Hiligsmann M, Bruyere O, Ethgen O, et al. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 2008; 43 (6): 991-4
2. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture inMalmo.Osteoporos Int 2000; 11 (8): 669-74
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17 (12): 1726-33 (Pubitemid 44607392)
4. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005; 16 (3): 229-38 (Pubitemid 40379422)
5. Kanis J, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19 (4): 399-428
6. Imaz I, Zegarra P, Gonzalez-Enriquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010 Nov; 21 (11): 1943-51
7. Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother 2009; 10 (14): 2303-15
8. Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009; 122 Suppl. 2: S3-13
9. Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21 (9): 1453-60 (Pubitemid 41368578)
10. Hiligsmann M, Rabenda V, Bruyère O, et al. The clinical and economic burden of non-adherence with osteoporosis medications. Health Policy 2010; 96: 170-7
11. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006; 17 (6): 914-21 (Pubitemid 43781506)
12. Sambrook P. Compliance with treatment in osteoporosis patients: an ongoing problem. Aust Fam Physician 2006; 35 (3): 135-7
13. Cummings SR, Martin JS,McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361 (8): 756-65
14. European Medicines Agency. CHMP assessment report for Prolia. London: European Medicines Agency, 2009 Mar 18[online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Public-assessment- report/human/001120/WC500093529pdf [Accessed 2010 July 27]
15. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 2010; 21 (5): 837-46
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (8): 1296-310 (Pubitemid 32804122)
17. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. 2nd ed. New York: Oxford University Press, 2007
18. Drummond M, Sculpher M, O'Brien B, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2007
19. Cleemput I, van Wilder P, Huybrechts M, et al. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009; 12 (4): 441-9
20. Hiligsmann M, Ethgen O, Bruyere O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009; 12 (5): 687-96
21. Dere W, Avouac B, Boers M, et al. Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998; 63 (2): 93-7 (Pubitemid 28347679)
22. Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15 (5): 507-14 (Pubitemid 29210953)
23. Autier P, Haentjens P, Bentin J, et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group.Osteoporos Int 2000; 11 (5): 373-80 (Pubitemid 30450118)
24. Gabriel SE, Tosteson AN, Leibson CL, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002; 13 (4): 323-30 (Pubitemid 34506742)
25. Melton 3rd LJ, Gabriel SE, Crowson CS, et al. Costequivalence of different osteoporotic fractures. Osteoporos Int 2003; 14 (5): 383-8
26. Bouee S, Lafuma A, Fagnani F, et al. Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries. Rheumatol Int 2006; 26 (12): 1063-72 (Pubitemid 44450839)
27. Hiligsmann M, Ethgen O, Bruyere O, et al. An economic evaluation of quantitative ultrasonometry as pre-screening test for the identification of patients with osteoporosis. Dis Manage Health Outcomes 2008; 16: 429-38
28. Hiligsmann M, Ethgen O, Richy F, et al. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008; 82 (4): 288-92
29. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001; 12 (5): 417-27 (Pubitemid 32606468)
30. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15 (4): 721-39 (Pubitemid 30174026)
31. Marshall D, Johnell O, Wedel H.Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312 (7041): 1254-9 (Pubitemid 26147662)
32. Kanis JA, Johnell O, Oden A, et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000; 27 (5): 585-90
33. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998; 8 (5): 468-89 (Pubitemid 28486716)
34. Boonen S, Kaufman JM, Reginster JY, et al. Patient assessment using standardized bone mineral density values and a national reference database: implementing uniform thresholds for the reimbursement of osteoporosis treatments in Belgium. Osteoporos Int 2003; 14 (2): 110-5 (Pubitemid 40824225)
35. Johnell O, Kanis JA, OdenA, et al. Predictive value ofBMDfor hip and other fractures. J Bone MinerRes 2005; 20 (7): 1185-94 (Pubitemid 40863806)
36. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35 (2): 375-82 (Pubitemid 38953182)
37. Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004; 15 (3): 175-9 (Pubitemid 38391531)
38. National Institute of Statistics. Directorate-General Statistics and Economic Information. Mortality tables 2004 and 2002-2004 Brussels: National Institute of Statistics, 2008
39. Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int 1998; 8 (6): 599-603 (Pubitemid 28566977)
40. Johnell O, Kanis JA, Oden A, et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15 (1): 38-42 (Pubitemid 38252438)
41. Cauley JA, Thompson DE, Ensrud KC, et al. Risk of mortality following clinical fractures. Osteoporos Int 2000; 11 (7): 556-61
42. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004; 15 (2): 108-12 (Pubitemid 38252423)
43. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003; 32 (5): 468-73 (Pubitemid 39665705)
44. Lips P, van Schoor NM. Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16 (5): 447-55
45. Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001; 44 (11): 2611-9 (Pubitemid 33049339)
46. Tosteson AN, Hammond CS. Quality-of-life assessment in osteoporosis: health-status and preference-based measures. Pharmacoeconomics 2002; 20 (5): 289-303 (Pubitemid 34569363)
47. Belgian Federal Government. FPS economy, SMEs, independent professions and energy: consumer price indexes. 2009 [online]. Available from URL: http://economie.fgov.be/fr/statistiques/chiffres/economie/prix-consommation/in dices-prix-consommation/index.jsp [Accessed 2010 Mar 1]
48. National Institute for Health and Clinical Excellence. Systematic reviews of clinical effectiveness prepared for the guideline 'Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk'. London: NICE, 2008 Sep [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/11621/42362/42362pdf [Accessed 2010 Mar 1]
49. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008; 19 (6): 811-8
50. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006; 38 (6): 922-8 (Pubitemid 44498580)
51. Belgian Center for Pharmacotherapeutic Information [online]. Available from URL: http://www.cbip.be/GGR/ MPG/MPG-NI.cfm#MP-04090 [Accessed 2010 Apr 1]
52. Greenspan SL, Emkey RD, Bone HG, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137 (11): 875-83 (Pubitemid 35416623)
53. Stock JL, Bell NH, Chesnut 3rd CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997; 103 (4): 291-7 (Pubitemid 27459255)
54. Strom O, Borgstrom F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries: an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007; 18 (8): 1047-61 (Pubitemid 47020004)
55. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010; 47 (1): 34-40
56. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96 (4): 972-80
57. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007; 18 (10): 1311-7 (Pubitemid 47389473)
58. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86 (3): 202-10
59. Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009; 20 (1): 23-34
60. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11 (1): 44-7 (Pubitemid 351160875)
61. HiligsmannM, Gathon HJ, Bruyere O, et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 2010; 13 (4): 394-401
62. Strom O, Landfeldt E, Robbins S, et al. Adherence to treatment of osteoporosis and fracture risk: the Swedish adherence register analysis (SARA) [abstract no. P109]. Osteoporos Int 2010; 21 Suppl. 1: S29
63. Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007; 18 (8): 1023-31 (Pubitemid 47019996)
64. Kendler DL, McClung MR, Freemantle N, et al. on behalf of the DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab and alendronate. Osteoporos Int. Epub 2010 Sep 9
65. Lewiecki EM. Is denosumab better than alendronate in the treatment of osteoporosis? Nat Clin Pract Rheumatol 2009; 5 (2): 72-3
66. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 14: 1-34
67. Cleemput I, Neyt M, Thiry N, et al. Valeurs seuils pour le rapport coǔt-efficacitéen soins de santé. Health Technology Assessment (HTA). Bruxelles: centre fédéral d'expertise des soins de santé(KCE), 2008 KCE Reports 100B (D/2008/10273/95)
68. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ2001; 323: 1300-3
69. Tosteson AM, Malton LJ, Dawson-Hughes B, et al. National Osteoporosis Foundation Guide Committee. Costeffective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 4: 437-47
70. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis: IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23 (4): 570-8 (Pubitemid 34925651)
71. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009; 30 (2): 213-21
72. Sheehy O, Kindundu CM, Barbeau M, et al. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009; 20 (8): 1369-76
73. Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006; 29 (12): 1133-52 (Pubitemid 44904829)
74. Borgstrom F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004; 22 (17): 1153-65 (Pubitemid 39665345)
75. Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010; 46 (2): 440-6
76. Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporos Int 2010; 21 (1): 157-65
77. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007; 120 (3): 251-6 (Pubitemid 46341156)
78. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19 (4): 385-97
79. Kanis JA, Oden A, Johansson H, et al. FRAX and its applications to clinical practice. Bone 2009; 44 (5): 734-43
80. Johansson H, Kanis JA, McCloskey EV, et al. A FRAX- model for the assessment of fracture probability in Belgium. Osteoporos Int 2011 Feb; 22 (2): 453-61
81. Kanis JA, Johnell O, De Laet C, et al. International variations in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002; 17 (7): 1237-44 (Pubitemid 34680500)